(Q36612328)

15 August 2017

1 reference

title

Biologic effects of interferons (English)

1 reference

15 August 2017

Biologic Effects of Interferons (English)

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

2 November 2022

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

2 November 2022

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

2 November 2022

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

2 November 2022

author name string

I. Gresser

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1701811

2 November 2022

language of work or name

English

0 references

publication date

1 December 1990

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:S0022202X9091192E?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

https://api.elsevier.com/content/article/PII:S0022202X9091192E?httpAccept=text/plain

2 November 2022

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Journal of Investigative Dermatology

2 November 2022

published in

1 reference

15 August 2017

volume

95

1 reference

15 August 2017

issue

6 Suppl

1 reference

15 August 2017

page(s)

66S-71S

1 reference

https://scigraph.springernature.com/pub.10.1111/1523-1747.ep12874776

15 August 2017

exact match

0 references

cites work

INTERFERON IN PROSPECT AND PERSPECTIVE

1

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

IMMUNOLOGIC, CHEMOTHERAPEUTIC AND INTERFERON APPROACHES TO CONTROL OF VIRAL DISEASE.

2 November 2022

2

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

INTERFERON. A REVIEW AND ANALYSIS OF RECENT OBSERVATIONS.

2 November 2022

3

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon's promise in clinical medicine. Fact or fancy?

2 November 2022

4

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Toward control of viral infections of man.

2 November 2022

9

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy

2 November 2022

13

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Effects of intradermal gamma-interferon in cutaneous leishmaniasis.

2 November 2022

14

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Short-course alpha-interferon therapy in severe unresponsive immune thrombocytopenic purpura

2 November 2022

17

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a

2 November 2022

18

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma.

2 November 2022

20

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma

2 November 2022

21

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo

2 November 2022

25

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Alpha interferon in human pregnancy

2 November 2022

26

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

The Presence of -Interferon in Human Amniotic Fluid

2 November 2022

27

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Unusual apparently constitutive interferons and antagonists in human placental blood

2 November 2022

28

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Normal human epidermis contains an interferon-like protein

2 November 2022

29

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Effect of exercise on plasma interferon levels

2 November 2022

30

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon messenger RNA is produced constitutively in the organs of normal individuals

2 November 2022

31

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

The physiological interferon response

2 November 2022

32

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Continuous production of interferon in normal mice: effect of anti-interferon globulin, sex, age, strain and environment on the levels of 2-5A synthetase and p67K kinase

2 November 2022

34

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon-induced protein Mx accumulates in nuclei of mouse cells expressing resistance to influenza viruses.

2 November 2022

35

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

A novel group of interferons associated with the early ovine and bovine embryo

2 November 2022

36

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus

2 November 2022

37

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors

2 November 2022

38

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Virus interference. I. The interferon

2 November 2022

39

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection

2 November 2022

43

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses

2 November 2022

44

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Enchancement of leukemogenesis in mice after prolonged administration of anti-interferon or normal rabbit globulin

2 November 2022

46

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. VI. Polyoma virus infection

2 November 2022

47

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Role of interferon in the pathogenesis of viral diseases of mice as demonstrated by the use of anti-interferon serum. V. Protective role in mouse hepatitis virus type 3 infection of susceptible and resistant strains of mice

2 November 2022

48

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Genetically determined, interferon-dependent resistance to influenza virus in mice

2 November 2022

49

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Host gene influences sensitivity to interferon action selectively for influenza virus

2 November 2022

51

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus

2 November 2022

52

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon independence of genetically controlled resistance to flaviviruses

2 November 2022

53

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

How does interferon inhibit tumor growth?

2 November 2022

54

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Antitumor effects of interferon

2 November 2022

56

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Cytokines in cancer therapy

2 November 2022

57

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

2 November 2022

58

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Disseminated Kaposi's sarcoma in AIDS: histogenesis-related populations and influence of long-term treatment with rIFN-alpha A

2 November 2022

59

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Treatment of haemangioendotheliomas with alpha interferon

2 November 2022

60

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells

2 November 2022

61

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon induces peripheral lymphadenopathy in mice

2 November 2022

62

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Involvement of interferon in virus-induced lymphopenia

2 November 2022

64

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Inhibition of lymphocyte recirculation by murine interferon: effects of various interferon preparations and timing of administration

2 November 2022

65

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Effect of interferon-alpha-2a on the output of recirculating lymphocytes from single lymph nodes

2 November 2022

66

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Can interferon induce disease?

2 November 2022

70

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Lethality of interferon preparations for newborn mice

2 November 2022

71

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon alpha/beta induces changes in the metabolism of polyenoic phospholipids and diacylglycerols in the livers of suckling mice

2 November 2022

72

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Progressive glomerulonephritis in mice treated with interferon preparations at birth

2 November 2022

73

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice

2 November 2022

74

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Delay in growth and the development of nephritis in rats treated with interferon preparations in the neonatal period

2 November 2022

75

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Interferon induces pulmonary cysts in A2G mice

2 November 2022

76

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice

2 November 2022

77

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus

2 November 2022

78

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Severity of lymphocytic choriomeningitis virus disease in different strains of suckling mice correlates with increasing amounts of endogenous interferon

2 November 2022

79

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

Severity of glomerulonephritis induced in different strains of suckling mice by infection with lymphocytic choriomeningitis virus: Correlation with amounts of endogenous interferon and circulating immune complexes

2 November 2022

80

1 reference

https://api.crossref.org/works/10.1111/1523-1747.EP12874776

2 November 2022

Identifiers

1 reference

Dimensions Publication ID

15 August 2017

1029521307

0 references

1 reference